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The aims of the study were to review the rapidly emerging COVID-19 literature to 
determine (a) the relationship between obstructive sle p apnoea (OSA) and adverse 
COVID-19 outcomes and, (b) potential causal mechanisms  (c) what effect COVID-
19 has had on OSA diagnosis and (d) what effect COVID-19 has had on treatment 
and management of OSA during this period. PubMed was systematically searched up 
to 020620. Studies were included if they had examined the relationship between 
COVID-19 and OSA. Studies were included that were in English and had the full text 
available. The findings from this study suggest tham ny of the risk factors and co-
morbidities associated for OSA which include obesity, hypertension and diabetes 
mellitus are associated with poor COVID-19 outcomes. There are plausible 
mechansims by which OSA may independently increase one’s risk of morbidity and 
mortality associated with COVID-19 and data from the newly published 
CORONADO study suggests that OSA treated patients may be at increased risk of 
death from COVID-19. It is clear that the pandemic has had a major effect on the 
treatment management and diagnosis of OSA and moving forward it may be 
necessary to explore new diagnosis and treatment pathways for these individuals.   
 

















AASM American academy of sleep medicine, 
ACE2 Angiotensin converting enzyme 2, 
AFSORL French Association of Otorhinolaryngology and Sleep disorders  
AHI Apnoea hypopnea index,  
ARDS Acute respiratory distress syndrome  
AST Aspartate transaminase 
AVAPS Average volume-assured pressure support 
COPD Chronic obstructive pulmonary disease, 
CORONADO Coronavirus SARS-CoV-2 and Diabetes Outcomes 
COVID-19 Novel coronavirus disease,  
CPAP Continuous positive airway pressure,  
EDS Excessive daytime sleepiness,  
EERS Enhanced expiratory rebreathing space,  
GERD Gastroesophageal reflux disease,  
IPF Idiopathic pulmonary fibrosis,  
NIV Non-invasive ventilation,  
NIPPV Non-invasive positive pressure ventilation,  
OSA Obstructive sleep apnoea,  
PPE Personal protection equipment,  
PRISMA Preferred reporting items for systematic reviews  
RASS Renin-angiotensin-aldosterone system,  
ROS Reactive oxgen species, 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus  2,  
SDB Sleep disordered breathing. 











The latter part of 2019 saw the emergence of a new coronavirus, Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), in Wuhan China. The virus has 
now reached global pandemic proportions. As of 26th June 2020, there have been 
9,612,250 confirmed cases of Novel coronavirus disease 2019 (COVID-19) due to 
infection of SARS-CoV-2 in the world, with 489,372 fatalities globally [1]. Some 
individuals are at greater risk from adverse outcomes associated with the disease. 
These include older adults, and those with respiratory and cardiovascular risk factors 
like, obesity and diabetes mellitus [2]. Furthermore, a disproportionate number of 
black and minority ethnic individuals have been affected by COVID-19. In England a 
third of confirmed cases admitted to critical care non-white [3] 
The sleep disorder, Obstructive sleep apnoea (OSA) is characterized by repetitive 
partial or complete blockages of the airway during sleep, leading to interruptions in 
breathing, blood oxygen desaturation and arousals from sleep. In the UK there are 
approx. 1.5M adults with OSA. It is associated with increased prevalence of 
hypertension (39%), obesity (34%), depression (19%), gastroesophageal reflux 
disease (GERD)(18%), diabetes mellitus (15%), hypercholesterolemia (10%), asthma 
(4%) [4]. Many of these factors have also been ident fi d as risk factors for poor 
COVID-19 outcomes [5]. It is unclear whether the virus might pose an increase risk 
for patients with OSA. 
The aims of this study were to conduct a systematic review to examine the potential 
relationship between COVID-19 severity and outcomes, and OSA, and to examine 
possible mechanistic pathways, and to determine what effect the COVID-19 












Search strategy and selection criteria  
Systematic searches using the Preferred reporting iems for systematic reviews 
guidelines (PRISMA) [6] to identify studies that reported the association between 
COVID-19 and OSA were performed.  Electronic searches were performed (from 
1966 to 2nd June 2020) of PubMed. The following “COVID-19 terms” (coronavirus 
OR corona-virus OR COVID OR COVID-19 OR COVID-2019 OR severe acute 
respiratory syndrome coronavirus  OR severe acute respiratory syndrome coronavirus 
2 OR 2019-nCoV" OR SARS-CoV-2  OR 2019nCoV) in combination with Sleep 
terms” (sleep OR sleep wake disorders OR sleep disturbance OR ("sleep apnoea 
syndromes OR  OSA OR OSAS OR sleep initiation and maintenance disorders OR 
insomnia OR bedtime OR "nightmare) were used. The articles identified by the 
searches were reviewed along with any relevant referenc s cited within them.  
Inclusion and Exclusion Criteria 
Papers were included if they examined the relationship between COVID-19 outcomes 
and OSA, or were related to the effect of COVID-19 pandemic on the diagnosis and 
treatment of this condition. 
Papers were excluded if the full paper was not avail ble or if they were not published 
in English.  
 
A total 251 potential studies were identified after r moval of duplicates (see figure 1). 
Abstract scanning yielded 26 for full text evaluation from which 17 were included for 












Of the 18 studies identified 8 were mainly related to risk of COVID-19 mortality and 
10 to diagnosis, treatment and management. 
 
OSA and COVID-19 morbidity and mortality  
Eight papers, seven from the original search [7,8,1,18,20,21,22] and one from 
reference searching [24] were examined. Of these five contained original data 
[17,18,20,22,24] (see table 1; part (a)); two were viewpoints [7,8]. Pazarlı et al [7] 
noted that common risk factors for COVID-19 mortality were shared with OSA, and 
these included increased age, hypertension, cardiovascular diseases, lung diseases, 
and diabetes mellitus.   Likewise, McCurry [8] also noted that morbidity and mortality 
worldwide were particularly high amongst those with these comorbidities but that 
obesity, which is also commonly associated with OSA, might also be important.  
Of the six studies with original data, Arentz et al demonstrated that OSA was 
present in 28% of the 21 patients with coronavirus disease who presented to their 
intensive care unit [24]. Likewise, Bhatraju et al found that 21% of patients with 
severe COVID pneumonia had OSA [17]. Gupta noted that of the first twenty-one 
patients admitted to a hospital in India with COVID-19 one had OSA [20].  
Memsoudis et al noted that of sixty ICU patients 8.3% had OSA and of the non-ICU 
patients 6.3% had OSA [21]. He reflected that as nearly all the patients were obese the 
number of expected OSA patients was low and might reflect under-diagnosis of this 










(CORONADO) study, aims to identify the clinical and biological features associated 
with risk of poor COVID-19 outcomes. In this study of people with diabetes 
hospitalized for COVID-19,  Cariou et al reported that treated obstructive sleep 
apnoea was independently associated with an increased risk of death on day 7 (OR 
2.80 [1.46, 5.38]) [18]. In a single case study a 74-year old male, with notable OSA, 
presented to hospital with hypoxia and dyspnea. He test d positive for COVID-19 but 
was successfully extubated and treated with average volume-assured pressure support 
(AVAPS) [22]. 
 
What are the potential mechanistic pathways by which COVID-19 may affect OSA 
patients? 
A number of different biochemical and inflammatory mechanisms are associated with 
the pathophysiology and progression of OSA and its associated poor health outcomes, 
some of which have also been associated with COVID-19 disease. The sleep-time 
disruptions in breathing that accompany OSA are associated with intermittent blood 
gas disturbances (hypercapnia and hypoxemia) and surges of sympathetic activation. 
Increased inflammatory markers have been reported in OSA but it remains to be 
determined if this is a result of the associated comorbidities [25]. Increased 
underlying inflammation however may be of particular importance in obese patients 
as potentially it may contribute to worsening hypoxemia and the cytokine storm [26] 
that occurs in COVID-19 pneumonia patients and in those with subsequent multi-
organ failure [26]. Results from a French study of 124 COVID patients indicated that 
obesity (BMI>30kg/m2) was a risk factor for invasive mechanical ventilation 










reported [27].  
Recent studies have suggested that the sleep hormone elatonin may be beneficial for 
the treatment of COVID-19 [28-30]. Melatonin may decrease oxidative stress, 
inflammation and the immune response, which may be particularly important in 
patients with OSA in whom these pathways are already activated. Activation of these 
pathways leads to a cytokine storm and subsequent progression to acute lung injury/ 
acute respiratory distress syndrome (ARDS) and often death. Melatonin may also 
improve sleeping quality, which might also be beneficial for better clinical outcomes 
for COVID-19 patients [28]. 
There is increasing evidence to suggest that vitamin D deficiency may be a risk factor 
for CVD [31]. Vitamin D may play an important role in the suppression of harmful 
reactive oxygen species (ROS) and inflammatory markers and may stimulate 
protective endothelial nitric oxide production [31]. In a study of 176 children, 
Kheinrandish-Gozal et al demonstrated that OSA was independently associated wi h 
higher hsCRP and lipids, and lower vitamin D [32]. Furthermore, multiple logistic 
regressions identified a strong effect of African American race on lower vitamin D 
levels, and showed the severity of OSA as measured by the Apnoea Hypopnea Index 
(AHI) correlated with lower vitamin D [32]. Vitamin D levels may be influenced by 
both diet and ethnicity. Vitamin D also enhances cellular immunity, in part by 
reducing the cytokine storm induced by the innate immune system and it has been 
suggested that low levels of vitamin D may in part be associated with poor COVID-19 
outcomes [33]. A recent study from the UK Biobank, however, did not find any 
evidence to support this [34]. They examined the data from 348,598 UK Biobank 










vitamin D was associated with COVID-19 infection this did not persist after 
adjustment for confounders. They concluded that ‘their findings did not support a 
potential link between vitamin D concentrations and risk of COVID-19 infection, nor 
that vitamin D concentration may explain ethnic differences in COVID-19 infection’ 
[34]. 
OSA is observed in a large proportion of individuals with resistant hypertension.  A 
recent meta-analysis demonstrated that OSA is associ ted with higher Angiotensin II 
and aldosterone levels, especially in hypertensive patients. It has been suggested 
therefore that OSA may lead to an increase in blood pressure through stimulation of 
the renin-angiotensin-aldosterone system (RAAS) [35]. The Angiotensin converting 
enzyme 2 (ACE2) has been identified as the entry receptor of SARS-CoV-2 [36] but 
unlike ACE, ACE2 does not convert Angiotensin I to Angiotensin II. Further 
investigation is therefore warranted to determine wh ther individuals, in whom there 
is an increased stimulation of the RASS from OSA, are at increased risk of the 
cardiovascular complications and comorbidities seen in COVID-19 patients.  
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that is associated with 
oxygen desaturations and pulmonary arterial hypertension. OSA is often reported in 
patients with IPF and recent IPF guidelines have recognised OSA as an important 
associated comorbidity that can affect patient's survival [37]. It is recommended that 
that newly diagnosed IPF patients should be referred to sleep centers for the diagnosis 
and treatment of OSA [38]. Fibrotic changes have also been seen in patients after 
COVID-19 [39]. It is therefore important that patients who have had COVID-19 and 
who have fibrotic changes are screened for potential OSA.  It is as yet unclear 










effects of COVID-19.  
 
The effect of COVID-19 pandemic on treatment and management of OSA. 
According to the available evidence, SARS-CoV-2 transmission occurs through 
droplets. Exhaled aerosol size depends on a number of factors including the 
characteristics of the fluid, the force and pressure at the moment of emission, and the 
environmental conditions [40]. Treatment of OSA with Continuous positive airway 
pressure (CPAP) improves health and wellbeing of patients and improves 
hypertension management and control in those with moderate-to-severe disease. 
CPAP is included in the non-invasive ventilation (NIV) category is included in the 
WHO list of high-risk aerosol-generating procedures [40].  The use of CPAP may 
therefore put those in its vicinity at increased risk of viral exposure and at a high risk 
of contagion [9]. It is for this reason that Barker et al has argued that community 
CPAP and NIV should be stopped unless it is medically necessary for life support 
[10]. They acknowledge that evidence is limited but s ggest that continued CPAP use 
might put other members of the household / carers at increased risk.  In response to 
this Baker and Sovani have argued that there are risks from stopping NIV and CPAP 
for patients [11]. See table 1; part (b) for more details.  
Cessation of CPAP treatment may be associated with a return of symptoms.  These 
may include effects on daytime sleepiness, concentration, memory and mood.   A 
return of symptoms, in particular, excessive sleepin ss, may also be harmful to the 
general public as a result of poor concentration and increased risk of performance 










OSA is a relatively common disorder with many of the 1.5 million individuals 
diagnosed in the UK alone being treated with CPAP. Given that the pandemic is 
affecting millions of people globally it is likely that many OSA CPAP–treated 
patients will be affected. Ways to reduce viral shedding from positive airway devices 
are therefore important.  Bacterial/ viral filters are being designed to trap particles and 
recently Kryger et al described how the use of Enhanced Expiratory Rebreathing 
Space (EERS) might help reduce viral shedding [12]. They suggest, however, that an 
individual with severe OSA who contracts COVID-19 might be best managed in a 
healthcare facility where staff might be able to take necessary precautions and use 
Personal Protection Equipment (PPE).  
In the UK, the British Sleep Society with the OSA Alliance (incorpating British 
Thoracic Society, British Sleep Society, Association f r Respiratory Technology and 
Physiology, Sleep Apnoea Trust Association) has just released guidelines with 
regards to the use of CPAP during the pandemic [42]. The guidance suggests that 
people with OSA should continue to use their CPAP at home as normal but suggests 
that individuals might wish to consider taking steps to distance themselves from 
vulnerable household members by changing bedrooms or stopping CPAP for a short 
time. It encourages patients to persist with CPAP when experiencing symptoms of 
respiratory infection. The current National Health Service guidance states, for 
patients, who remain at home during the coronavirus pandemic, to continue with their 
usual method of ventilation.  
In France, the French Association of Otorhinolaryngolo y and Sleep disorders 
(AFSORL) and the French Society of Otorhinolaryngolo y (SFORL) put forward a 










these new practice conditions [23] see table 1; part (b). Interestingly, in a separate 
study of 7485 patients it was noted that compliance to CPAP improved during 
lockdown compared with data one month before and when compared with the same 
period the preceding year. It was suggested that this may be the result of publicity 
regarding COVID-9, which has described as a disease that affects the airways and, a 
fear of hospitalization may have motivated patients to adhere to treatment. Spending 
more time at home might have also led to Increased opportunity to sleep and to use 
the CPAP treatment [23].  
Oral devices may also be used for the treatment for OSA. Given that many dental 
procedures generate aerosols there is a concern that viral droplets may remain 
suspended in the air. Thus whilst oral appliance treatments may be low-risk 
procedures there may be risk to sleep patients fromother procedures conducted at 
dental practices. Likewise, due to the transmission risk, the procedures for cleaning 
oral sleep appliances, which include mandibular advancement appliance for snoring 
and sleep apnea, may need to be reviewed. [14] 
 
The effect of COVID-19 on OSA diagnosis 
OSA is very prevalent worldwide, and given that the comorbidities of OSA patients 
are shared with those of COVID-19 patients who experience adverse outcomes it may 
be of great importance to ensure that OSA patients receive effective CPAP therapy if 
confronted with COVID-19 infection. Despite this, COVID-19 has had a major effect 
on sleep services both in the UK and elsewhere (see tabl  1; part (c)).  A recent study 










sleep disordered breathing (SDB) in patients in nineteen European countries [15]. In 
31 of the total 40 participating centers patients were unable to physically attend 
because of travel restrictions. It was found that mjor changes to the services provided 
occurred during the pandemic.  For the diagnosis of OSA it was reported that, prior to 
COVID-19 pandemic, 92.5% used in lab Polysomnography, 87.5% used Polygraphy 
at home and 30% used Telemedicine. During the pandemic, in lab polysomnography 
had significantly reduced to 20%, at home Polygraphy to 32.5% and Telemedicine 
based diagnosis was used in 27.5%. They also reported that commencement of 
treatment for SDB by various types of positive airwy pressure therapy were equally 
reduced in the vast majority of centres and countries. Furthermore, staffing levels in 
the sleep medicine service was reduced to 25% for physicians and to 19% for 
nurses/technicians compared to pre-pandemic levels. 
[15] 
 
In China, in high epidemic areas, such as Wuhan and the nearby cities in Hubei 
province, sleep study and non-invasive positive pressure ventilation (NIPPV) were 
suspended except in case of emergency whereas for areas with low COVID-19 it was 
decided that in lab sleep studies could be performed in ‘at risk’ individuals providing 
the possibility of COVID-19 infection could be excluded and with the proviso that 
appropriate PPE is available and virus control procedure are followed. Other sleep 
services and follow up appointments are provided via online services [13].  
 
In the US, the American Academy of Sleep Medicine (AASM) issued revised 
recommendations on 27th April 2020 that include the postponement of in-laboratory 










consideration is given to using single-use, fully disposable devices and/or 
components. If  reusable devices are used these must be cleaned and sanitized 
according to CDC disinfection standards and manufact rer’s instructions and that 
personnel should have appropriate PPE. It advises that a reusable device should be 
removed from service for at least 72 hours in addition o disinfection before its next 
use [43]. Similar procedures should be followed for h me testing and the use of a mail 
delivery service would ensure that patients do not have to leave their home to receive 
or return the device. [16,43]. Telemedicine may play a more important role in the 
diagnosis and management of these conditions. For individuals who do need to be 
seen in sleep clinics it is clear that measures to screen individuals arriving at the 
clinics as well as increased personal protection measures and sanitization measures 
need to be implemented. New procedures for the treatment of patients requiring 
ventilation who become infected with COVID-19 may be required to prevent spread 
to staff, carers or family members [16]..  
 
Discussion  
This comprehensive systematic literature review is consistent with a recent study of 
1099 COVID-19 patients, which did not specifically look at OSA, but which showed 
higher rates of chronic obstructive pulmonary disease (COPD), diabetes and 
hypertension in patients who were admitted to intensive care units, required 
mechanical ventilation or died [44]. In the majority of the reviewed studies it has not 
been possible to establish whether OSA is simply a co-morbidity that is associated 
with Covid-19 morbidity and mortality or whether is it potentially and independent 










examined this in more detail [18]. Data published online on May 29th, documents the 
clinic characteristics of the 1317 individuals with diabetes, in the study prior to 
admission to hospital with coronavirus symptoms; of these 1189 individuals had 
treated OSA. The study demonstrated that dyspnea, lymphocyte count, C-reactive 
protein and AST measured on admission were independent predictors of the primary 
outcome of tracheal intubation and /or death at day 7. Age, treated obstructive apnoea 
and microvascular and macrovascular complications were also independently 
associated with risk of death at day 7 [18]. Further studies are therefor warranted to 
establish this potentially causal relationship between OSA and COVID-19 outcomes, 
both in individuals with and in those without diabetes. 
In the UK it has been estimated that more than 85% of potential cases of OSA remain 
undetected [45], and so potentially there could be a large number of unidentified 
individuals who may be at increased risk from COVID-19.  
There are a number of plausible pathways by which COVID-19 might have an 
adverse effect on OSA patients and further research is warranted to investigate these 
pathways. Furthermore, given that recent studies suggest that melatonin may be 
beneficial for the treatment of COVID-19 [28-30] it remains to be seen if sleep and 
treatment for sleep disorders may have beneficial effects on COVID-19 outcomes. 
Many COVID-19 patients suffer pulmonary fibrosis which itself is a risk factor for 
future development of OSA.  Careful monitoring of discharged patients for 
thrombotic and fibrotic effects and subsequent OSA development are warranted.   
Moving forward it is necessary that guidelines are reviewed so that as new knowledge 










these restrictive pandemic conditions may be developed. Many sleep laboratory teams 
have been assisting with the respiratory effects suffered by COVID-19 patients and it 
is clear for ‘normal‘ sleep services to resume, all sleep center stuff including 
physicians, sleep technicians and respiratory physiotherapists or respiratory nurses 
will need ongoing training in updated clinical knowledge of the COVID-19 pandemic. 
It will be necessary to continually review the practices and to develop new safe 
operating procedures with reference to the guidelines from the government, scientific 
societies and national authorities.  
The emergence of disposable kits for overnight sleep studies is important as they may 
provide a new and safe way for the diagnosis of sleep conditions, under these 
restrictive conditions. 
Conclusions 
The findings from this study suggest that many of the risk factors for OSA are 
associated with poor COVID-19 outcomes. There are plausible mechansims by which 
OSA may be associated with poor outcomes and further studies are required to 
corroborate the data from the CORONADO study which suggests that treatment for 
OSA is independently associated with risk of death from COVID-19. The pandemic 
has had a major effect on the treatment management and diagnosis of OSA and 
moving forward it may be necessary to explore new diagnosis and treatment pathways 
for these individuals. This may include the increased telemedicine and the use of 
disposable diagnostic tools and non-contact sleep surveillance for sleep apnoea 
diagnosis. Those already diagnosed but awaiting treatm nt may need priority at this 












A review of the current diagnosis, treatment and management protocols for OSA may 
be required in light of the COVID-19 pandemic 
1.  Common risk factors and co-morbidities for OSA are shared with those individuals 
who have poor COVID-19 outcomes; 
2.  There are plausible mechanistic pathways by which COVID-19 may have adverse 
effects on OSA and treated OSA patients may be at increased risk of death from 
COVID-19; 
3.  COVID-19 has had major effects on the treatment, management and diagnosis of 
OSA during the pandemic;  
4. Moving forward sleep centres may need to establish new ways to diagnose patients 
with OSA, potentially using robust decontamination procedures for reusable 
equipment or disposable sleep study kits;   
5. The management and treatment of existing patients will need to be changed, 




In the future we need to be able to safely and effectiv ly diagnose and manage OSA 
and to: 
1.  Determine whether questionnaire based screening programmes or disposable sleep 
tests can be used for OSA detection; 
2. Corroborate the data that suggest that individuals treated for OSA may be at 
increased risk of death from COVID-19; 
3. Determine whether any adverse risk from COVID-19 for OSA patients can be 
modified by effective treatment compliance. 
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Figure Captions  



















Study details Main results and Authors’ conclusions Strengths and 
Limitations  
Part (a) OSA and COVID-19 morbidity and mortality  
Arentz et al  
2020 24 
Case Series (n=21) 
Patients with confirmed 
SARS-CoV-2 infection 
admitted to the ICU at 
Evergreen Hospital, 
Washington State.  
Feb 20th -5thMarch 2020 
Mean age, 70 years [range, 43-92 years]. 52% men. Comorbidities were identified in 18 cases (86%), with 
chronic kidney disease and congestive heart failure being the most common. 28.6% of patients had obstructive 
sleep apnoea. 
Mechanical ventilation was initiated in 71% of patients. As of March 17, 2020, mortality was 67% and 24% of 
patients remained critically ill. Emphasizes the ned to limit exposure of nursing home residents to SAR -
CoV-2.  
Small number 
from a single 




nursing facilities  
Bhatraju et al 
2020 17 
Case series (n=24) min 
14 days follow up. 
Patients from nine 
Seattle-area hospitals, 
admitted to ICU with 
confirmed SARS-CoV-
2. February 2020 
Mean age 64+/-18years, BMI 33.2+/- 7.2Kg. 63% men. 58% had diabetes mellitus, 22% were current or 
former smokers, 21% had chronic kidney disease, 21%had obstructive sleep apnoea, 14% had asthma. All the 
patients were admitted for hypoxemic respiratory failure, 75% of the patients required mechanical ventilation. 
50% died. 
The most common reason for admission to ICU was hypoxemic respiratory failure requiring mechanical 
ventilation. Mortality was high. 
Small sample size. 





Nationwide study in 53 
French centers  
10th –31st March 2020. 
The primary outcome was combined tracheal intubation for mechanical ventilation and/or death within 7 days 
of admission. 1317 participants: 64.9% men, mean age 69.8 ± 13.0 years, median BMI 28.4 (25th–75th 
percentile: 25.0–32.7) kg/m2; with a predominance of type 2 diabetes (88.5%)  
Age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 
2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with 
the risk of death on day 7. 
OSA is an independent risk factor for risk of death in COVID-19 patients.  
 
Gupta 2020  
et al 20 
Case series (n=21) of 
the first COVID-19 
patients admitted to a 
tertiary care center in 
India. 
1st Feb-19th March 2020 
The mean age of the population was 40.3 years (range 16-73 years). There was a male preponderance 
(66.7%). All patients were Indian.  
Six patients (28.6%) had comorbidities. The most comm n comorbidity was hypertension (5 patients) and 
diabetes mellitus (3 patients) adequately controlled with drugs. One (4.8%) patient with hypertension and one 
with diabetes mellitus also showed anxiety disorder and hypothyroidism. Another patient had an underlying 
migraine and obstructive sleep apnoea. As of 19th March 19 of the patients had been discharged 
Small sample size. 
Memtsoudis et al 
2020 21 
Case series (n=124) of 
whom 60 in ICU and 64 
non-ICU 
In ICU the average BMI was: males, 28.3 [SD 5.3] (n=44) of whom 5 had OSA and females, 30 [6.3] (n=16) 
of whom none had OSA. In patients severely ill with respiratory failure but not in ICU and therefore not
requiring mechanical ventilation) the average BMI was: males, 29 [6.1] (n=35) of whom 2 had OSA and 
females average BMI, 33.5 [12.1] (n=21) of whom 2 had OSA. The authours hypothesise that the low 
incidence of diagnosed OSA in a high-risk obese patient population may reflect under-diagnosis. 
 









Part (b) The effect of COVID-19 pandemic on treatment and management of OSA 
Attias et al 2020 19  In a cohort of 7485 patients with OSA the impact of he coronavirus disease (COVID-19) national lockdown 
in France on objective adherence to CPAP was assessed by telemonitoring. 
Data was compared from the pre-COVID-19 period (one month before 15 March 2020, the date of the nationl 
lockdown announcement) to data post-lockdown. There was a 3.9 % (p<0.001) increase in adherence from a 
mean value of 386 min per night pre-COVID-19 to 401 min per night during lockdown.  
These data were confirmed by comparing the CPAP adherence rate during the first month of lockdown (15th 
March 2020 to 15th April 2020). 
The proportion of very low adherers (less than 10 minutes of CPAP use per night) dropped by 18.5 % 
(p<0.001) between the similar periods in 2019 and 2020).   
The authours hypothesise that fear of being hospitalized may have motivated patients to increase CPAP 
adherence and decreased occupational stress and increased opportunity for sleep may be important.  
Large sample size 
Prospective 
cohort. 
Baker & Sovani  
2020 11 
Opinion piece Summary of main points: 
NIV: This is primarily used for those with previous, or at risk from, hypercapnic respiratory failure).  
1. Stopping home NIV risks the return of symptoms (lethargy, headache, dyspnoea and confusion), increased 
patient and family anxiety and precipitating life-threatening acute hypercapnia,  
2. Home NIV patients often have limited mobility or are housebound. There is therefore a higher risk of a 
carer to patient transmission.  
3. There is a risk to carers from infected patients. The use of a non-vented mask with a viral filter reduces will 
reduce viral spread.  
4.  Measures to reduce viral load in a room (e.g. by opening windows and doors) should be employed. Use of 
PPE will be required.  
For patients in care facilities hospitals use of a side room and change of mask and circuit with a virl f lter 
should minimise risk.  
CPAP: This is primarily used for those with OSA.  
1. CPAP treatment improves symptoms (sleepiness, headaches, concentration, memory and mood) but is rarely 
life preserving.  
2. Stopping home CPAP may cause deterioration in physical and mental health. Increased sleepiness will 
affect driving and safety critical jobs and work productivity may fall.  
3. The return of snoring may had adverse effects on family members.  
4. Stopping CPAP for the entire epidemic duration ca not be recommended, especially for those with safety- 
critical jobs and those with increased workload during the pandemic.  
5. If a CPAP- user develops symptoms (or has asympto atic proven COVID-19) then self-isolation and 
stopping CPAP for 2 weeks might be sensible.  
6. Patients not to bring home CPAP equipment to hospital  for inpatient admissions.  
7. Patients with decompensated obesity hypoventilation or COPD/OSA overlap will be provided with a non-
vented mask, viral filter and vented circuit in a side room with a hospital CPAP machine.  
Whilst there is an unknown, potentially increased, risk of viral transmission for other household membrs and 










withhold home NIV and CPAP for all users, for what may be a substantial period (maybe 12 weeks or even 
longer), will cause significant, and measurable, patient harm. 
Barker et al 
2020 10 
Opinion piece The authors summarise existing evidence which suggests that:   
- NIV-induced aerosols secretions from asymptomatic patients may pose high-dose viral transmission risks in 
households.
  
- Isolation may be required following NIV usage.  
- Universal isolation for NIV and CPAP usage within   households may not be practical.  
- Individualized consideration should be given to temporary cessation of community ventilation.  
The authors believe there is a risk of high-dose viral transmission from CPAP users to household members, 
with potentially severe consequence. Clearer instructions for patients and their physicians regarding isolation 
or cessation of treatment are required.  
Non-systematic 
Bastier et al 2020 
23 
 The French Association of Otorhinolaryngology and Sleep disorders (AFSORL) and the French Society of 
Otorhinolaryngology (SFORL) put forward a summary of the measures for continuing the treatment of sleep 
apnoea syndrome in these new practice conditions. Emphasis is placed on teleconsultation, the conditions f r 
treatment by CPAP, and the postponement of more invas ve treatments 
 
Kryger & Thomas  
2020 12 
 The authors describe a new method to reducing viral shedding in COVID-19 patients on PAP devices. The 
new circuit elements are designed to vent exhaled air away from the patient and impose a filter before th  air 
can exit the system  
As at home, it may be difficult protect others, it may be better to treat patients with severe OSA and COVID-
19 infection in a healthcare facility.  
Non-systematic 
Lance et al 
2020 9 
Review Summary main points: 
PAP therapy may increase the risk of transmission of COVID-19 to others in the environment. 
PAP therapy user should sleep in a separate bedroom and use a separate bathroom where possible.  
PAP equipment should be diligently cleaned. 
For infected patients it may be reasonable to discontinue PAP or to maintain strict quarantine.  
AASM recommendations include: Postponing in-laboratory sleep studies for all patients.  
Postponing home sleep apnea testing unless using disposable testing devices.  
Sleep clinics should remain open for phone calls, te emedicine visits, and emergency in-person visits only.  
Basic continuous PAP and bilevel PAP devices are not a substitute for the use of a ventilator in the setting of 
acute respiratory failure. 
Should the need arise to use PAP/NIV devices to assist with mild hypoxemia and hypercapnia pending 
endotracheal intubation, adaptations will need to be made to the mask and filtration systems.  
Non-systematic 
Lavigne et al 
2020 14 
 Whilst oral appliance treatments are normally low-risk procedures, dental and sleep medicine professionals 
may have to review the required levels of protection required, for patients, families, and staff, with respect to 
COVID-19. There are a number of issues that need to be addressed including whether mouth-breathing 
sleepers, patients with positive disease history, and “healthy”  carriers pose risks for their sleep partners. And, 
are greater precautions now needed when cleaning oral sleep appliances? 










Part (c) The effect of COVID-19 on OSA diagnosis 
Grote et al 
2020 15  
Questionnaire study  
25 of 29 sleep centers 
from the European 
Sleep Apnoea Database 
(ESADA) and 15 of 283 
accredited sleep centres 
of the German Sleep 
Society (DGSM).  
Prior to the pandemic, laboratory-based polysomnography was performed in 92.5% of centres v 20% during 
the pandemic (p<0.001).  
Telemedicine- based sleep apnoea diagnosis was used in 30.0% of centres prior to the pandemic v 27.5% 
during the pandemic.  
Prior to the pandemic, laboratory-based CPAP or bi-level PAP titration and initiation were practiced in almost 
all centres but less than one fifth of centres continued this routine during the pandemic (p<0.001).  
Prior to the pandemic, 39 centres report regular follow-up procedures in patients with SDB. This service 
continued in 36 centres during the pandemic but the mode of follow up had changed. The majority of centers 
provided follow-up by phone or video-calls.  
Staffing levels in the sleep medicine service was reduced to 25% (Interquartile range (IQR) 40) for physicians 
and to 19% (IQR 28) for nurses/technicians compared to pre-pandemic levels.  
 
1) European sleep medicine services have been reduced by almost 80% during the first 1-2 months of the 
COVID-19 pandemic.  
2) More comprehensive sleep studies have been completely interrupted, or practiced only to a very limited 
extent. 3) Commencement of treatment for SDB has been r duced.  
4) Patient follow-up is mainly via telemedicine  









Drummond 2020 16 Review Summary points include: 
1. Polysomnography sleep studies should be avoided. 
2. Use of equipment that cannot be sterilized adequat ly should be avoided. 
3. The entire sleep lab teams need to be provided with ongoing receive training pertinent to COVID-19 
4. Full PPE needs to be available. 
5. Telemedicine should be used for existing patients 
6. Patients under NIV infected by SARS-CoV-2 should be changed to non-vented masks, provided with filter 
in the circuit. Equipment needs to changed and cleaned post-infection.  
7. Non-emergency diagnostic or therapeutic procedure should be postponed. 
 
During the COVID-19 pandemic doctors should avoid unnecessary procedures that put patients and health 
care professionals at risk of infection.  




Zhang & Xiao 
2020 13  
Findings overview from 
task force 
Chinese sleep centers 
Task force 
commissioned by the 
Chinese Thoracic 
The aim of the task force was to develop a consensus on sleep study and NIPAP treatment during the epidemic 
of COVID-19 in China. 
Recommendations include: 
1.  High epidemic area: Sleep study and NIPPV suspended, except in case of emergency.  
2. Areas with only sporadic cases or small clusters:  Sleep study & NIPAP continued, use portable home sle p 
study and auto-adjusting PAP at home. Use disposable equipment where possible.  












Society 3. Low epidemic area, in lab sleep study and NIPAP could be initiated after confidently ruling out the 
possibility of COVID-19 
4.  For sleep technicians appropriate PPE must be used and equipment cleaned and disinfected.  
5. Telemedicine to be used where possible.  
 
The best infection prevention and control practices and the optimization of diagnosis and treatment pro ocol 
for sleep disorders during this outbreak should be eveloped based on the epidemic situation, culture, he 
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